Intellia Therapeutics Inc (NTLA)

138.79
+2.22(+1.63%)
After Hours
138.79
0.00(0.00%)
- Real-time Data
  • Volume:
    726,308
  • Bid/Ask:
    135.68/139.68
  • Day's Range:
    131.88 - 138.97

NTLA Overview

Prev. Close
136.57
Day's Range
131.88-138.97
Revenue
51.52M
Open
136.26
52 wk Range
16.54-202.45
EPS
-2.46
Volume
726,308
Market Cap
10.08B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,238,502
P/E Ratio
-
Beta
2.14
1-Year Change
620.99%
Shares Outstanding
72,648,954
Next Earnings Date
Aug 05, 2021
What is your sentiment on Intellia Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Intellia Therapeutics Inc News

Intellia Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyBuySellStrong Buy
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Buy

Intellia Therapeutics Inc Company Profile

Intellia Therapeutics Inc Company Profile

Employees
312

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

Read More
  • time to buy a few and hold me thinks
    0
    • Any thought about this stock?
      0
      • waiting to get back in
        0
        • Feels too aggressive
          0
          • GLOP and CEPU, this are the next homeruns
            0
            • Buy????
              0
              • I'm really surprise about how empty this forum is on a day like this!
                0
                • crazy move though....would like to see more on Crisper on follow through
                  0
                • What do you mean? It's just you and i.. nobody else is posting a reaction here.
                  0
                • I'm just bugging you! in a friendly way! Your right but if the crystal ball was working you wouldn't have been surprised is what I mean
                  0
              • https://www.fiercebiotech.com/biotech/first-human-trial-results-intellia-shows-world-gene-editing-has-arrived
                0
                • Great news for investors in Intellia and other similar companies using Crispr cas9
                  0
              • what's happening here
                0
                • Be patient guys, just hold and fly to the moon!🚀🚀
                  0
                  • Read Jennifer Doudna's book guys before you make an investment into this company.
                    1
                    • I cant tell if this a positive or negative comment?
                      0
                    • pls a bit more straightforward. whats the insight you got?
                      1
                    • 9
                      0
                  • What was that from +11 percent -2 percent?what happened?
                    0
                    • Boom! Out.
                      0
                      • Looks like this is ready to pop any day now.
                        0
                        • NTLA is gonna run up into the 17 to 18 dollar range by the end of january. This is not trading advice
                          1
                          • nice prediction :) Jan 31 - trading at 12.57 :)
                            0
                          • he was a month and half off end of Feb into March
                            0
                        • Inept workers + inept managers = worthless bottom! I was right.
                          1
                          • emmmmm.... lol
                            0
                        • Touch the bottom? 12, 11 or 10? Target 9?
                          0
                          • wish it can go up to 40 + after Feb
                            1
                            • Profit source has NTLA at $18 by end of january. So we can hope. This is not trading advice or stratedgy
                              0
                          • $NTLA has both analyst saying “BUY” with an ave 12 month target price of $35.50 which is 109% at its closing price of $16.96
                            0
                            • That is 109% ROI
                              0
                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.